Eligibility estimates contract from ~13.3 million with obesity/overweight to ~3.8 million Bridge-eligible Part D enrollees after excluding diabetes, OSA, MASH, and current GLP‑1 users. Modeled ...

VRBPAC endorsed mRNA-1010 for adults 50-64 and ≥65 years, unanimously concluding benefits outweighed risks, supporting a late-stage regulatory path toward potential first mRNA seasonal influenza ...

Secret-shopper testing showed 91.8% of online sellers issued GLP-1 RA prescriptions and 69.4% shipped medication, often within one day and sometimes within minutes. Intake workflows commonly lacked ...

Among insulin-treated, CGM-naive adults, CGM initiation in primary care produced larger HbA1c reductions at 12 months and ...

The growing list of insurers dropping coverage for costly GLP-1 weight loss drugs leaves patients to bear even higher out-of-pocket expenses while still struggling to ...

Eli Lilly’s deals add late- and early-stage vaccine assets: a potentially better-tolerated shingles candidate, bacterial ...

The rarity of sarcoma complicates clinical trial design and biomarker-driven treatment, explains Alexander Spira, MD, PhD, ...

As discussed at a recent IVBM event, Robert Kratzke, MD, outlines essential biomarkers, NGS panel selection, and next steps ...

CDC ended the federal response June 24, 2026, after risk diminished, releasing >100 deployed staff from the peak incident ...

AML management now hinges on molecularly defined subtypes, supported by numerous targeted approvals; expanding trial access ...

IDOV-Safe leverages an unusually high extracellular enveloped virion proportion (~60%) to support true intravenous oncolytic virus delivery despite circulating neutralizing proteins. The phase 1 ...

Minhee Kang, PharmD, discusses 3 key considerations for oncology pharmacists to improve treatment safety, patient education, ...